Pulse Biosciences’ nPulse™ Technology Featured at Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences will showcase its nPulse™ Cardiac Catheter technology at the Heart Rhythm Society 2026 Annual Meeting, where they will present updates from late-breaking clinical trials and one-year outcomes of a European feasibility study.
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes